GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » Quick Ratio

Avecho Biotechnology (ASX:AVE) Quick Ratio : 8.19 (As of Dec. 2023)


View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Avecho Biotechnology's quick ratio for the quarter that ended in Dec. 2023 was 8.19.

Avecho Biotechnology has a quick ratio of 8.19. It generally indicates good short-term financial strength.

The historical rank and industry rank for Avecho Biotechnology's Quick Ratio or its related term are showing as below:

ASX:AVE' s Quick Ratio Range Over the Past 10 Years
Min: 3.21   Med: 6.31   Max: 15.09
Current: 8.19

During the past 13 years, Avecho Biotechnology's highest Quick Ratio was 15.09. The lowest was 3.21. And the median was 6.31.

ASX:AVE's Quick Ratio is ranked better than
74.38% of 1542 companies
in the Biotechnology industry
Industry Median: 3.6 vs ASX:AVE: 8.19

Avecho Biotechnology Quick Ratio Historical Data

The historical data trend for Avecho Biotechnology's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Quick Ratio Chart

Avecho Biotechnology Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 7.58 4.29 6.63 3.28 8.19

Avecho Biotechnology Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.63 6.11 3.28 2.14 8.19

Competitive Comparison of Avecho Biotechnology's Quick Ratio

For the Biotechnology subindustry, Avecho Biotechnology's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Avecho Biotechnology's Quick Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Avecho Biotechnology's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Avecho Biotechnology's Quick Ratio falls into.



Avecho Biotechnology Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Avecho Biotechnology's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(7.004-0.097)/0.843
=8.19

Avecho Biotechnology's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(7.004-0.097)/0.843
=8.19

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Avecho Biotechnology  (ASX:AVE) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Avecho Biotechnology Quick Ratio Related Terms

Thank you for viewing the detailed overview of Avecho Biotechnology's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Avecho Biotechnology (ASX:AVE) Business Description

Traded in Other Exchanges
Address
Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168
Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sale, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology (ASX:AVE) Headlines

No Headlines